Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and
nontraditional risk factors. Genome-wide association combined with clonal lineage tracing …

It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

Background: Although guidelines recommend in-hospital initiation of high-intensity statin
therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol …

The current COVID-19 epidemic has greatly accelerated the application of mRNA
technology to our real world, and during this battle mRNA has proven it's unique advantages …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease
synthesized primarily by the liver. It mainly promotes the degradation of low-density …

Background and aims Proprotein convertase subtilisin/kexin 9 (PCSK9) has emerged as a
popular target in the development of new cholesterol-lowering drugs and therapeutic …

Intraplaque release of inflammatory cytokines from macrophages is implicated in
atherogenesis by inducing the proliferation and migration of media smooth muscle cells …

The proprotein convertase subtilisin/kexin-type 9 (PCSK9) binds to low-density lipoprotein
receptors (LDLR), thereby trafficking them to lysosomes upon endocytosis and enhancing …

Proprotein convertase subtilisin/kexin Type 9 (PCSK9) is now identified as an important and
major player in hypercholesterolaemia and atherosclerosis pathophysiology. PCSK9 …

Hypercholesterolemia is a major risk factor for cardiovascular diseases, increasing the
incidence of myocardial infarction and death. Statin-induced lowering of low-density …